



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01N 33/543, 33/68	A1	(11) International Publication Number: WO 99/15898 (43) International Publication Date: 1 April 1999 (01.04.99)
(21) International Application Number: PCT/US98/19693 (22) International Filing Date: 22 September 1998 (22.09.98) (30) Priority Data: 60/059,703 22 September 1997 (22.09.97) US 60/083,921 1 May 1998 (01.05.98) US (71) Applicant: CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 04608-2916 (US). (72) Inventors: CHIEN, David, Y.; 1121 Douglass Court, Alamo, CA 94507 (US). ARCANGEL, Phillip; Apartment 103, 2541 Regent Street, Berkeley, CA 94704 (US). TIRELL, Stephen; 287 Prospect Street, Franklin, MA 02038 (US). ZIEGLER, Wanda; 5A Winthrop Street, Medway, MA 02032 (US). (74) Agent: PAINTIN, Francis, A.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: METHOD FOR DETECTING ANTIBODIES IN A SAMPLE (57) Abstract <p>The present invention is directed to assays for detecting antibodies e.g. to Hepatitis C virus in a sample in a single incubation step. The assays employ universal solid phases and/or universal detectable markers, and facilitate the detection and differentiation of antigens from the same source or from different sources in a single test sample. The present invention includes test kits for performing the methods according to the invention.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR DETECTING ANTIBODIES IN A SAMPLE

This application claims priority benefit under 35 U.S.C. § 119 to application serial numbers 60/059,703 and 60/083,921, hereby incorporated by reference in their entireties.

5 FIELD OF THE INVENTION

The present invention relates to the detection/quantitation of antibodies against antigens in a sample.

BACKGROUND OF THE INVENTION

Antibody capture assays are generally used for the detection of antibodies
10 directed to particular antigens in a sample. The detection of such antibodies provides information concerning not only exposure to particular antigens, but can also provide information concerning progression of disease. Antibody capture assays that utilize solid-phase antigens, however, do not allow the measurement of real antibody titers in a sample. Assays for the detection and/or quantitation of at least two different substances
15 in a test sample have been described. U.S. Patent No. 5,395,752 (the '752 patent), incorporated herein by reference, describes chemiluminescent compounds as detectable markers for use in the detection of at least two substances in a test sample. Chemiluminescent compounds which emit light at different wavelengths with minimal overlap are utilized. The detectable markers, i.e., chemiluminescent compounds,
20 however, are specific for the particular substance to be detected/quantitated in the test sample.

A method for assaying antibodies in a test sample that facilitates

- 2 -

measurement of real titers, can accommodate the detection of different antibody species directed against the same source in a test sample, as well as accommodate the detection of different antibodies against different sources in a test sample is needed.

SUMMARY OF THE INVENTION

5 In one aspect, the present invention relates to a method for the detection/quantitation of antibodies to a particular target antigen in a sample in a single incubation step.

 In another aspect, the present invention relates to a method for the detection/quantitation of antibodies to at least two antigens from the same source in a
10 single test sample in a single incubation step, using a single detectable marker.

 In yet another aspect, the present invention relates to a method for the detection/quantitation of antibodies to at least two antigens from the same source in a single test sample in a single incubation step, using at least two light reagents which emit light at different wavelengths as the detectable markers.

15 In a further aspect, the present invention relates to a method for the detection of antigens from more than one source in a single test sample, in a single incubation step, using light reagents which emit light at different wavelengths as the detectable markers. In a further aspect, the present invention relates to a method for the determination of an antibody profile and real antibody titer for a particular source in test
20 samples from a single subject using a single detectable marker.

 In a further aspect, the present invention relates to test kits for performing the methods according to the invention. In the kits according to the invention, the solid phase and detectable marker can be stored in the same compartment.

BRIEF DESCRIPTION OF THE DRAWINGS

25 Figure 1 depicts an exemplary assay format according to the invention.

DETAILED DESCRIPTION

 The practice of the present invention will employ, unless otherwise indicated, conventional methods of virology, immunology, microbiology, molecular biology and recombinant DNA techniques within the skill of the art. Such techniques
30 are explained fully in the literature. See, e.g., Sambrook, et al., *Molecular Cloning: A Laboratory Manual* (2nd Edition, 1989); *DNA Cloning: A Practical Approach*, Vols. I

- 3 -

& II (D. Glover, ed.); *Methods In Enzymology* (S. Colowick and N. Kaplan eds., Academic Press, Inc.); *Handbook of Experimental Immunology*, Vols. I-IV (D.M. Weir and C.C. Blackwell eds., Blackwell Scientific Publications); and *Fundamental Virology*, 2nd Edition, Vols. I & II (B.N. Fields and D.M. Knipe, eds.).

- 5 Assays for the detection of antibodies against a single target antigen, multiple target antigens from the same source, or multiple target antigens from different sources in a single test sample, that can be performed in a single incubation step (i.e., simultaneously) are described. The assays can be performed on a high throughput, automated system and, thus, allow for data renormalization. The assays according to the
- 10 invention exhibit high sensitivity (100%) and specificity (99.5 - 99.7% on blood donor samples). Universal solid phases and/or universal detectable markers are employed.

The following definitions are employed herein.

The term "target antigen" as used herein includes single epitope and multiple epitope antigens, as well as haptens.

- 15 The term "source" as used in reference to the target antigens herein includes, without limitation, viruses, bacteria, tumors, fungi, etc. The different sources can be, for example, different subtypes of a virus, different viruses, or a virus and a bacteria.

- 20 The term "ligand" as used herein refers to a binding partner. In preferred embodiments, the ligands are superoxide dismutase ("SOD") and ubiquitin.

- The term "detectable marker" as used herein includes, but is not limited to, a chromophore, an enzyme, an enzyme reactive compound whose cleavage product is detectable, rhodamine, biotin, streptavidin, a fluorescent compound, a chemiluminescent compound, and derivatives and/or combinations of these markers. In the examples
- 25 provided, the chemiluminescent compound dimethyl acridinium ester (DMAE, Ciba Corning Diagnostics Corp.) was used. Labeling with any marker is carried out under conditions for obtaining optimal detection and binding of the antibody.

- The means for detecting the detectable markers will depend upon the marker used. The appropriate means, and conditions, can be readily determined by one
- 30 of ordinary skill in the art. As set forth in the examples below, when DMAE is the detectable marker in an assay, the resultant anti-ligand-DMAE conjugate is the tracer,

- 4 -

with DMAE detectable by light emission when reacted with NaOH/H₂O₂. In the assays involving two or more light reagents, at least two photomultiplier tubes must be utilized to obtain the measurements.

The labeling of individual antigens with detectable markers can be very tedious and, further, the resultant label may not be stable. The present invention provides for a universal detectable marker. In the present invention, the antigens are coupled to a ligand, e.g., an antigen/ligand fusion protein. This fusion protein is paired with a detectable marker comprising an antibody directed against the ligand. The antibody directed against the ligand is coupled to the detectable marker. Many different antigens can be fused to the same ligand. In this manner, numerous antigens can be detected with a single, universal marker.

The term "subject" as used herein refers to the source of the test sample, and includes, without limitation, humans and other vertebrates. In a preferred embodiment, the subject is human. The term "test sample" as used herein refers to any biological fluid from a subject in which antibodies against the target antigens may be present including, but not limited to, serum and plasma.

"Anti-subject immunoglobulin antibodies" refers to antibodies directed against immunoglobulins from the subject in general. In a preferred embodiment, the anti-subject immunoglobulin antibodies are rat anti-human immunoglobulin (Ig). In a more preferred embodiment, the anti-subject human antibodies are rat anti-human IgG. The anti-subject immunoglobulin antibodies are coupled to the solid phase providing, thus, a universal solid phase for detecting/quantitating antibody in a test sample.

The solid phase can be paramagnetic microparticles ("PMP"), magnetic latex particles ("MLP"), or microtiter plates. Preferably, the particles are less than approximately 10 μ m in diameter.

The test kits according to the invention also include calibrators or controls. As noted above, in preferred embodiments, the target antigens are coupled to the ligands as fusion proteins. For example, the antigens can be expressed as internal antigens within the yeast *S. cerevisiae* as C-terminal fusions with human SOD using methods described previously for the generation of the c100-3 (NS4, 363 aa) Hepatitis C virus antigen. Kuo *et al.*, *Science*, **1989**, 244, 362-364, incorporated herein by

- 5 -

reference in its entirety; and Cousens *et al.*, *Gene*, **1987**, *61*, 265-275, incorporated herein by reference in its entirety. The c33c antigen (NS3, 363 amino acids) has also been expressed as an internal SOD fusion polypeptide in *E. coli* by methods described for the synthesis of 5-1-1 antigen. Choo *et al.*, *Science*, **1989**, *244*, 359-362,

5 incorporated herein by reference in its entirety. The recombinant HCV antigens were purified as described in Chien *et al.*, *Proc. Natl. Acad. Sci. USA*, **1989**, *89*, 10011-10015. In the specific examples detailed below, all antigens were prepared as SOD fusion proteins. However, other suitable fusion proteins can be made depending upon the availability of appropriate antibodies that recognize the fusion partner ligand.

10 MEFA-6 is a multiple epitope antigen and contains epitopes from the core, envelope, NS3, NS4 and NS5 regions of the hepatitis C polyprotein, including equivalent antigenic determinants from HCV strains 1, 2, and 3. The various DNA segments coding for the HCV epitopes were constructed by PCR amplification or by synthetic oligonucleotides. MEFA-6 antigen includes multiple copies of HCV epitopes
15 from the core and NS5 region; different serotype epitopes from the NS4 5-1-1 region; a single copy of major linear epitopes from the c100 C-terminal regions, E1, and E2 regions, as well as the HCV NS3 (c33c) region. The general structural formula for the MEFA-6 fusion protein is hSOD-E1-E2-c33c-5-1-1(type 1)-5-1-1(type 3)-5-1-1(type 2)-c100-NS5(2 copies)-core(2 copies). This antigen has a very high expression level in
20 yeast, purifies to a high degree of homogeneity, and exhibits high sensitivity and high selectivity in the immunoassays described below. MEFA-6 was prepared as described in application PCT US97/08950 filed May 23, 1997, incorporated herein by reference in its entirety.

Anti-SOD-DMAE was used as the universal detectable marker. The anti-
25 SOD antibody was labeled with DMAE by reaction of amino acid side chains (e.g. lysine ϵ side chain or cysteine thiol) with a reactive moiety covalently linked to DMAE (see WO 95/27702, published October 19, 1995, Ciba Corning Diagnostics Corp., herein incorporated by reference in its entirety). Thiols of amino acid side chains can be labeled using DMAE-ED-MCC or NSP-DMAE-PEG-BrAc (Ciba Corning). Labeling
30 procedures were generally as described in WO 95/27702, incorporated herein by reference, with variations in conditions as necessary for each antigen to provide optimal

- 6 -

detection and antigenicity.

Sensitivity was reported as the optical density of the assay sample divided by the assay detection cut off in optical density units (s/co). All known negative samples exhibited s/co values less than 1.

5 EXAMPLES

Example 1: Manual Assay

A Magic Lite Analyzer System II (MLA II) is used for the manual assay. Parameters such as volume, concentration, time, and temperature are provided for guidance, but may be adjusted accordingly. Briefly, a 10 μ l aliquot of test sample was
10 added to five separate 75 x 12 mm test tubes for obtaining an antibody profile for HCV. To each tube, 100 μ l of sample diluent or buffer, 100 μ l of solid phase buffer containing paramagnetic particles (PMP) conjugated to rat anti-human IgG antibodies (PMP/anti-human IgG, 30 μ g/assay), 50 μ l HCV antigen/SOD fusion proteins (core (c22-3, 50 ng), NS3 (c33c, 100 ng), NS4 (c-100-3 100 ng), NS4 (5-1-1 100 ng), and NS5 (100 ng), and
15 100 μ l anti-SOD conjugated to DMAE (30 million relative light units, "RLU") in ligand reagent (LR) diluent were added, and incubated for 18 minutes at 37°C. The solid phase/Lite reagent diluent buffer comprised 50 mM Tris, 0.5 M KCl, 1 mM disodium EDTA, 3.75 % BSA, 0.003 % Yeast, 0.05 g/L *E. coli* extract, 0.5 % Tween-20, 2 mg/L Amphotericin B, 24 mg/L Gentamicin Sulfate, 30 μ g/test Solid Phase and 45 x 10⁶ test
20 Lite Reagent (anti-SOD*DMAE antibodies). The ancillary diluent buffer comprised 50 mM Tris, 0.5M KCl, 1 mM disodium EDTA, 3.75 % BSA, 0.003 % Yeast, 0.05 g/L *E. coli*, 0.5 % Tween-20, 2 mg/L Amphotericin B, 24 mg/L Gentamicin Sulfate, 0.05 g/L Ascites IgG1 and 0.1 g/L Ascites IgG2A (blocking antibodies). The wash reagent comprised PBS/Tween-20. The acid reagent comprises 0.5 % H₂O₂/0.1 N HNO₃. The
25 base reagent comprises <0.25N NaOH with surfactant.

The sample tubes were placed on a magnet for sufficient time to sediment the PMP particles. The samples were decanted using a magnet to retain the PMP particles. The PMP particles were washed twice with vortexing in 1 mL of PBS. The wash solution was PBS, 0.1 % Tween-20, 0.09 % NaN₃, and 1 mM EDTA. The steps of
30 mixing, incubating, sedimenting and decanting may be repeated at least one time. To each tube 100 μ l of water was added to resuspend the PMP particles. The tubes were

- 7 -

then placed in an MLA-II instrument and light emission measured for 2 seconds.

Results, using chronic paid donor samples, are presented in Table 1.

Example 2: Comparison of Automated Assay with Other Commercial Assays

The manual anti-HCV assay described above was adapted for automated use using an ACS:Centaur apparatus. The following procedure is used. Briefly, the ACS:Centaur system automatically performs the following steps: 1) dispenses 10 μ l of sample into a cuvette; 2) dispenses 100 μ l of ancillary diluent buffer, 100 μ l of Lite Reagent/Solid Phase, 50 μ l of antigen reagent 2 (e.g., MEFA-6), 50 μ l of antigen reagent 1 (e.g., c33c) and incubates the mixture for 18 minutes at 37°C; 3) separates the solid phase from the mixture and aspirates the unbound reagent; 4) washes the cuvette with wash reagent 1; 5) dispenses 300 μ l each of acid reagent and base reagent to initiate the chemiluminescent reaction; and 6) reports results according to the selected option, as described in the system operating instructions or in the online help system.

The solid phase/Lite reagent diluent buffer comprised 50 mM Tris, 0.5 M KCl, 1 mM disodium EDTA, 3.75% BSA, 0.003% Yeast, 0.05 g/L *E. coli* extract, 0.5% Tween-20, 2 mg/L Amphotericin B, 24 mg/L Gentamicin Sulfate, 30 μ g/test Solid Phase and 45 x 10⁶ test Lite Reagent (anti-SOD*DMAE antibodies). The ancillary diluent buffer comprised 50 mM Tris, 0.5M KCl, 1 mM disodium EDTA, 3.75% BSA, 0.003% Yeast, 0.05 g/L *E. coli*, 0.5% Tween-20, 2 mg/L Amphotericin B, 24 mg/L Gentamicin Sulfate, 0.05 g/L Ascites IgG1 and 0.1 g/L Ascites IgG2A (blocking antibodies). The wash reagent comprised PBS/Tween-20. The acid reagent comprises 0.5% H₂O₂/0.1 N HNO₃. The base reagent comprises <0.25N NaOH with surfactant.

Results were compared to the Ortho 3.0, Abbott 3.0, and RIBA® 3.0 assays using commercially available seroconversion panels and are depicted in Table II. Results for the Ortho, Abbott, and RIBA® assays are provided by the vendors for the seroconversion panels: BBI (BBI) refers to Boston Biomedica Incorporated and BCP refers to BioClinical Partners. PHV is a prefix to designate the panel name. Lots #1 through #4 refer to multiple lots of reagents from dits (reagent compartment plus solid phase).

As is evident from the results, the assay according to the present invention allowed the detection of antibody several bleeds earlier than Ortho 3.0 and Abbott 3.0.

- 8 -

The RIBA® assay confirms HCV invention.

Example 3: Sensitivity of Automated Assay

The sensitivity of the assay according to the present invention was ascertained in a test population of 510 patients that screened positive in the Ortho 3.0 assay. Assay conditions were as described above. The results of the testing are depicted in Table III. In the Table, "IVDA" refers to IV drug abuse, "STD" refers to sexually transmitted disease, "N" refers to the number of samples in each group tested, and "RR" refers Repeat Reactive. Samples that are initially reactive (positive) in the assay are retested; if the sample is reactive (positive) upon repeat testing it is considered "Repeat
10 Reactive."

As is seen from Table III, all samples which tested positive for HCV in the RIBA® 3.0 assay were Repeat Reactive using the assay according to the present invention.

Example 4: Assay for Multiple Viruses in a Single Sample

15 Assay conditions are as described in Example 3 above with the exception that a different ligand and different light reagent are used for each antigen. MEFA-6-SOD is used and detected with anti-SOD-DMAE; c33c-ubiquitin is used and detected with anti-ubiquitin-LEAE (long wavelength emitting acridinium ester).

The foregoing examples are meant to illustrate the invention and are not
20 to be construed to limit the invention in any way. Those skilled in the art will recognize modifications that are within the spirit and scope of the invention. All references cited herein are hereby incorporated by reference in their entirety.

- 9 -

HCV Multi-Antigen assay: anti-SOD*DMAE format on the MLA II

		HCV recombinant SOD Fusion antigens				
		50ng/assay	100ng/assay	100ng/assay	100ng/assay	100ng/assay
		Core (c22-3)	NS-3 (c33c)	NS-4 (c-100-3)	NS-4 (5-1-1)	NS-5
		s	s	s	s	s
HCV Chronic paid donor samples	LL57385	111804	nd	2156	1709	nd
	96727	54993	385524	6622	2880	74921
	FF2594	32848	264803	59829	162193	2880
	FF2589	509909	nd	7330	20174	nd
	FF2587	20913	nd	5159	2094	nd
random negatives	r1	8100	1001	2079	1032	2526
	r2	7839	1232	1958	955	2649
	r3	5606	1032	1833	1201	3018
	r4	7099	1170	1432	1155	2402
		7161	1109	1826	1086	2649
		s/co	s/co	s/co	s/co	s/co
	LL57385	5.2	nd	0.4	0.5	nd
	96727	2.6	115.9	1.2	0.9	9.4
	FF2594	1.5	79.6	10.9	49.8	0.4
	FF2589	23.7	nd	1.3	6.2	nd
	FF2587	1.0	nd	0.9	0.6	nd

cutoff equal or greater than 1.0 is positive

TABLE I

- 10 -

Table II
Seroconversion Sensitivity of ACS:Centaur HCV Assay
(Earlier Detection)

		Ortho 3.0					Abbott 3.0					RIBA 3.0				
		Lot #1	Lot #2	Lot #3	Lot #4	Index	Lot #1	Lot #2	Lot #3	Lot #4	S/CO	c100	c33	c22	NS5	SOD
BBI	PHV905-02	4	0.2	0.5	0.3	0.3	0.0	0.1	-	-	-	-	-	-	-	NEG
	PHV805-03	7	0.4	0.5	0.4	0.4	0.0	0.1	-	-	-	-	-	-	-	NEG
	PHV905-04	11	1.3	1.3	1.4	1.4	0.2	0.1	-	-	-	1+	-	-	-	IND
	PHV905-05	14	1.6	1.7	1.7	1.6	0.6	0.2	-	-	-	1+	-	-	-	IND
	PHV905-06	18	3.2	2.9	2.9	3.0	1.0	0.3	-	-	-	1+	+/-	-	-	IND
	PHV905-07	21	6.7	5.8	5.7	5.6	2.3	0.6	-	-	-	2+	1+	-	-	POS
	PHV905-08	25	16.0	15.5	16.4	13.5	4.6	3.4	-	-	-	4+	4+	-	-	POS
	PHV905-09	28	38.6	34.1	38.3	32.6	>4.9	>4.9	-	-	-	4+	4+	-	-	POS
BBI	PHV907-03	7			0.3	0.3	0.0	0.1	-	-	-	-	-	-	-	NEG
	PHV907-04	13			0.5	0.4	0.1	0.2	-	-	-	-	1+	-	-	IND
	PHV907-05	18			1.8	1.4	0.5	0.8	-	-	-	+/-	4+	-	-	IND
	PHV907-06	21			3.9	3.2	1.0	1.4	-	-	-	1+	4+	-	-	POS
	PHV907-07	164					>5.0	>5.0	-	-	-	-	-	-	-	-
BCP 6214 (61083)	6214-06	18	0.3	0.3			0.0		-	-	-	-	-	-	-	NEG
	6214-07	23	0.3	0.4			0.0		-	-	-	+/-	-	-	-	NEG
	6214-08	25	0.5	0.5			0.0		-	-	-	+/-	-	-	-	NEG
	6214-09	30	2.0	2.1			0.9		-	-	-	+/-	2+	-	-	IND
	6214-10	32	3.3	3.2			2.6		-	-	-	+/-	3+	-	-	IND
	6214-11	49	28.1	25.4			4.1		2+	4+	-	-	-	-	-	POS

TABLE III

Sensitivity of ACS:Centaur HCV4.0 Assay Using
Populations (n=510) Screened Positive with Ortho HCV 3.0

	<u>N</u>	<u>RR</u>	<u>Confirmed</u>	<u>Sensitivity</u>
Hemophiliac	10 ^a	9	9	100%
IVDA	32 ^b	31	31	100%
Dialysis	20	20	20	100%
STD	56 ^c	54	54	100%
Hospital	65 ^d	58	58	100%
Egyptian, Chinese				
Brazilian, Japanese	138 ^e	137	137	100%
Verified HCV Serology	189	189	189	100%

^a One sample was RIBA 3.0 negative

^{b,e} One sample was RIBA 3.0 indeterminate (c33c)

^c One was RIBA 3.0 indeterminate (NS5), 1 was RIBA 3.0 negative

^d 5 were RIBA 3.0 indeterminate (3-c22, 1-NS5, 1-c33), 2 were RIBA 3.0 negative

CLAIMS

We claim:

1. A method for detecting/quantitating antibodies to a target antigen in a test sample from a subject, said method comprising;
 - 5 a) simultaneously incubating said test sample with i) solid phase anti-subject immunoglobulin antibodies, ii) the target antigen coupled to a ligand, and iii) an anti-ligand antibody coupled to a detectable marker to effect a reaction between iv) anti-target antigen antibodies in the test sample from the subject, i) the solid phase anti-subject immunoglobulin antibodies, ii) the target antigen coupled to a ligand, and iii) the
10 anti-ligand antibody coupled to a detectable marker; and
 - b) detecting the detectable marker by appropriate means.
2. The method of claim 1 wherein said target antigen is at least one epitope of Hepatitis C virus.
3. The method of claim 2 wherein said target antigen contains at least
15 two epitopes of Hepatitis C virus.
4. The method of claim 2 wherein said target antigen is an NS3 antigen from Hepatitis C virus.
5. The method of claim 3 or 4 wherein said ligand is SOD.
- 20 6. The method of claim 3 or 4 wherein said detectable marker is a chemiluminescent reagent.
7. The method of claim 6 wherein said chemiluminescent reagent is an acridinium ester.
8. The method of claim 1 wherein said target antigen coupled to a
25 ligand is a fusion protein.

- 13 -

9. A method for detecting/quantitating antibodies to two or more target antigens in a test sample from a subject, wherein said target antigens are from the same source, said method comprising

- 5 a) simultaneously incubating said test sample with i) solid phase anti-subject immunoglobulin antibodies, ii(a) a first target antigen coupled to a ligand, ii(b) at least a second target antigen coupled to said ligand, and iii) anti-ligand antibodies coupled to a detectable marker to effect a reaction between iv) anti-first target antigen antibodies in the test sample from the subject, i) said solid phase anti-subject immunoglobulin antibodies, ii(a) the first target antigen coupled to a ligand, and iii) the
10 anti-ligand antibody coupled to a detectable marker and between v) anti-second target antigen antibodies in the test sample from the subject, i) said solid phase anti-subject immunoglobulin antibodies, ii(b) the at least second target antigen coupled to said ligand, and iii(a) the anti-ligand antibody coupled to a detectable marker; and
b) detecting the detectable marker by appropriate means.

15 10. The method of claim 9 wherein said source is Hepatitis C virus.

11. The method of claim 9 wherein said first target antigen is an NS3 antigen from Hepatitis C virus.

12. The method of claim 9 wherein said at least a second target
20 antigen is a core antigen from Hepatitis C virus.

13. The method of claim 11 or 12 wherein said ligand is SOD.

14. The method of claim 11 or 12 wherein said detectable marker is a chemiluminescent reagent.

15. The method of claim 14 wherein said chemiluminescent reagent is
25 an acridinium ester.

- 14 -

16. The method of claim 10 wherein said target antigen coupled to a ligand is a fusion protein.

17. A method for detecting/quantitating antibodies to two or more target antigens in a test sample from a subject, wherein said target antigens are from
5 different sources, said method comprising
a) simultaneously incubating said test sample with i) solid phase anti-subject immunoglobulin antibodies, ii(a) a first target antigen coupled to a first ligand, ii(b) at least a second target antigen coupled to a second ligand, iii) anti-first ligand antibodies coupled to a first light reagent, and iii(a) at least an anti-second ligand
10 antibody coupled to a second light reagent to effect a reaction between iv) anti-first target antigen antibodies in the test sample from the subject, i) said solid phase anti-subject immunoglobulin antibodies, ii(a) the first target antigen coupled to a first ligand, and iii) the anti-first ligand antibody coupled to a first light reagent and between v) anti-second target antigen antibodies in the test sample from the subject, i) said solid phase
15 anti-subject immunoglobulin antibodies, ii(b) the at least second target antigen coupled to a second ligand, and iii(a) the anti-second ligand antibody coupled to a second light reagent, wherein said first and at least said second light reagents emit light of detectably different wavelengths; and
b) detecting the emission signal of each of said light reagents.

20 18. The method of claim 17 wherein said different sources are subtypes of the same virus.

19. The method of claim 17 wherein said different sources are different viruses.

25

20. The method of claim 17 wherein said first ligand is SOD.

21. The method of claim 17 wherein said second ligand is ubiquitin.

- 15 -

22. The method of claim 17 wherein said chemiluminescent reagent is an acridinium ester.
23. The method of claim 17 wherein said target antigens coupled to a ligand are fusion proteins.
- 5 24. A test kit for the detection of antibodies directed to one or more target antigens in a test sample in a single incubation step, wherein said target antigens are from the same source, said test kit comprising solid phase anti-subject immunoglobulin antibodies, at least a first target antigen coupled to a first ligand, an anti-first ligand antibody coupled to a detectable marker, and a means for the detection
10 of said detectable marker.
25. The test kit of claim 26 wherein said ligand is SOD.
26. The test kit of claim 26 wherein said detectable marker is a chemiluminescent reagent.
27. The test kit of claim 26 wherein said detectable marker is an
15 acridinium ester.
28. The test kit of claim 26 wherein the solid phase anti-subject immunoglobulin antibodies and detectable marker are stored in the same compartment.
29. The test kit of claim 24 further comprising a second target antigen coupled to said first ligand.
- 20 30. A test kit for the detection of antibodies directed to two or more target antigens in a test sample in a single incubation step, wherein said target antigens are from different sources, said test kit comprising solid phase anti-subject immunoglobulin antibodies, a first target antigen coupled to a first ligand, at least a

- 16 -

second target antigen coupled to a second ligand, an anti-first ligand antibody coupled to a first light reagent, at least an anti-second ligand antibody coupled to a second light reagent, wherein said first and at least said second light reagents emit light emission signals of detectably different wavelengths, and a means for the detection of the
5 emission signal of each of said light reagents.

31. The test kit of claim 30 wherein said detectable marker is a chemiluminescent reagent.

32. The test kit of claim 30 wherein said detectable marker is an acridinium ester.


10 33. The test kit of claim 30 wherein said first ligand is SOD.

34. The test kit of claim 30 wherein said second ligand is CPK.

35. The test kit of claim 30 wherein the solid phase anti-subject immunoglobulin antibodies and detectable marker are stored in the same compartment.

FIGURE 1

ACS:Centaur™ HCV 4.0 Assay



Single 18 min Incubation

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19693

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01N33/543 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 44469 A (CHIRON CORP) 27 November 1997 see page 36, line 4 - page 38, line 2 see figures 5,6 ---	1-35
A	WO 94 26932 A (US ARMY) 24 November 1994 see page 4, line 15 - page 5, line 30 see page 17, line 16 - page 18, line 3 see page 20, line 5 - line 26 ---	1-35
X	WO 94 24560 A (INT MUREX TECH CORP ;DUNCAN RICHARD JULIAN STUART (GB); BECKFORD U) 27 October 1994 see claims see page 7, line 5 - line 22 see page 12, line 17 - page 13, line 14 see page 16, line 21 --- -/--	1-35



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

9 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Routledge, B

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 98/19693

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 14403 A (BAXTER DIAGNOSTICS INC) 22 July 1993 see claims see page 10, line 1 - page 12, line 11 ---	1-35
X	WO 92 08979 A (ABBOTT LAB) 29 May 1992 see claims see claims see page 6, line 13 - line 20 see page 7, line 8 - line 21 ---	1-35
X	US 4 737 453 A (PRIMUS FREDERICK J) 12 April 1988 see claims see column 1, line 40 - line 45 see column 3, line 21 - line 29 ---	1,9,17, 24,29,30
X	FR 2 556 840 A (IMMUNOTECH SA) 21 June 1985 see claims see page 2, line 6 - line 16 see page 3, line 1 - line 13; figure 2 -----	1-35

INTERNATIONAL SEARCH REPORT

Information on patent family members

In. ational Application No

PCT/US 98/19693

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9744469 A	27-11-1997	AU 3214397 A	09-12-1997
WO 9426932 A	24-11-1994	AU 6913394 A	12-12-1994
WO 9424560 A	27-10-1994	AU 6508694 A	08-11-1994
		CA 2137786 A	27-10-1994
		CN 1105181 A	12-07-1995
		CZ 9403150 A	17-01-1996
		EP 0646241 A	05-04-1995
		FI 945857 A	13-12-1994
		GB 2282884 A	19-04-1995
		JP 7508102 T	07-09-1995
		SK 153594 A	11-07-1995
WO 9314403 A	22-07-1993	AU 3422993 A	03-08-1993
		CA 2104596 A	07-07-1993
		EP 0575597 A	29-12-1993
		JP 6505803 T	30-06-1994
WO 9208979 A	29-05-1992	AU 650503 B	23-06-1994
		AU 9104991 A	11-06-1992
		CA 2095825 A	10-05-1992
		EP 0556331 A	25-08-1993
		JP 6501559 T	17-02-1994
US 4737453 A	12-04-1988	AU 5070785 A	19-06-1986
		CA 1254828 A	30-05-1989
		EP 0188093 A	23-07-1986
		JP 61144573 A	02-07-1986
FR 2556840 A	21-06-1985	NONE	

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.